Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 14.8% in December

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 10,900 shares, a decline of 14.8% from the December 15th total of 12,800 shares. Based on an average daily volume of 28,500 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.2% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research report on Wednesday.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for about 0.5% of Stonepine Capital Management LLC’s holdings, making the stock its 21st largest holding. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Price Performance

Shares of APRE stock traded up $0.31 during trading hours on Friday, hitting $4.06. The stock had a trading volume of 21,165 shares, compared to its average volume of 41,725. The stock’s 50-day moving average price is $3.34 and its two-hundred day moving average price is $3.46. Aprea Therapeutics has a one year low of $2.15 and a one year high of $8.85. The stock has a market capitalization of $22.02 million, a price-to-earnings ratio of -1.44 and a beta of 0.75.

Aprea Therapeutics (NASDAQ:APRE) last posted its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.11. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The firm had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.45 million. As a group, equities research analysts predict that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.